Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients

Myasthenia Gravis (MG) is mediated by autoantibodies against acetylcholine receptors that cause loss of the receptors in the neuromuscular junction. Eculizumab, a C5-inhibitor, is the only approved treatment for MG that mechanistically addresses complement-mediated loss of nicotinic acetylcholine re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lekova, Eleonora, Zelek, Wioleta M., Gower, David, Spitzfaden, Claus, Osuch, Isabelle H., John-Morris, Elen, Stach, Lasse, Gormley, Darren, Sanderson, Andrew, Bridges, Angela, Wear, Elizabeth R., Petit-Frere, Sebastien, Burden, Michael N., Priest, Richard, Wattam, Trevor, Kitchen, Semra J., Feeney, Maria, Davis, Susannah, Morgan, B. Paul, Nichols, Eva-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486540/
https://www.ncbi.nlm.nih.gov/pubmed/36148231
http://dx.doi.org/10.3389/fimmu.2022.968206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486540/
https://www.ncbi.nlm.nih.gov/pubmed/36148231
http://dx.doi.org/10.3389/fimmu.2022.968206

Ejemplares similares